Aimmune Therapeutics Inc. (NASDAQ:AIMT) shares shot up 1.8% during mid-day trading on Monday . The company traded as high as $14.80 and last traded at $14.66, with a volume of 114,894 shares changing hands. The stock had previously closed at $14.40.

A number of brokerages have issued reports on AIMT. Zacks Investment Research raised Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday, May 20th. Bank of America Corp. reissued a “buy” rating on shares of Aimmune Therapeutics in a report on Monday, May 16th. Piper Jaffray Cos. reissued an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a report on Tuesday, May 17th. Credit Suisse Group AG reissued a “buy” rating and set a $35.00 price objective on shares of Aimmune Therapeutics in a report on Friday. Finally, Wedbush reissued an “outperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, May 16th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Aimmune Therapeutics has a consensus rating of “Buy” and an average price target of $33.40.

The stock’s 50-day moving average price is $11.90 and its 200-day moving average price is $13.80. The firm’s market capitalization is $630.85 million.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.01. Equities analysts predict that Aimmune Therapeutics Inc. will post ($1.71) EPS for the current fiscal year.

In other Aimmune Therapeutics news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the company’s stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $15.23, for a total value of $3,655,200.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

An institutional investor recently raised its position in Aimmune Therapeutics stock. RS Investment Management Co. LLC boosted its position in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 12.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 804,143 shares of the company’s stock after buying an additional 88,180 shares during the period. RS Investment Management Co. LLC owned approximately 1.90% of Aimmune Therapeutics worth $14,836,000 as of its most recent filing with the SEC.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.